Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
about
Treatment for inclusion body myositisImmunosuppressant and immunomodulatory treatments for multifocal motor neuropathyImmunosuppressant and immunomodulatory treatments for multifocal motor neuropathyImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyImmunosuppressant and immunomodulatory treatments for multifocal motor neuropathyIntractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporinScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesChronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedsideChronic inflammatory demyelinating polyneuropathyMultifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variantsTherapeutic advances and future prospects in immune-mediated inflammatory myopathies.A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.Mycophenolate mofetil and neurological diseases.A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy.Treatment of Guillain-Barré syndrome and CIDP.Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation.Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Basic immunosuppressive drugs outside solid organ transplantation.Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal.Evidence-based treatment of chronic immune-mediated neuropathies.Treatment in inflammatory neuropathies.Update on treatment of inclusion body myositis.Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Mycophenolate in treatment-resistant inflammatory neuropathies.[The clinical spectrum of dermatomyositis].
P2860
Q24186948-25925DF5-FC88-46AB-A123-CAEB7007B664Q24187418-090E9AEC-0545-4986-B427-AEA56AAE1335Q24200228-495E40AF-54E3-4010-A51E-6F19A11B67EEQ24201954-B3E2664C-4FDD-4283-BC67-C1EE5A2AF1E1Q24236599-7DD213CB-EBAD-40FD-9B4F-1547ED3A32C9Q24241391-A0E058D8-8F45-44C2-B8A0-CC05E2D60D51Q24670327-5B819946-44BB-4498-909E-9EF5F22045CEQ26798209-03A7889B-D166-4D62-9915-B2178641EF0FQ26823910-FD7DA642-CF2F-4375-85EA-DD7A9F28ADEEQ28384089-E27BB815-4416-49BB-BC1D-695EF7B6B956Q28390264-9E7425F5-0147-4AC3-85EB-5F32F8667C6DQ34409105-F19D5302-B05F-4BE6-9675-D191FCFF9C60Q34409297-7812041A-6067-4D55-81E0-2876B49A58E6Q34409308-27F70176-85EF-4F9E-9453-EA1837EA7D2AQ35991443-F9CD564A-06A0-42A5-BBD1-2CE6D690FE10Q36085865-9E8C87C7-7E50-4D24-A57D-862FF53E5245Q36150688-A3695255-0255-44E0-BC8E-E5B658E1F342Q36164126-E83A2EE1-ACA5-4FBE-87AD-7C80C83A4EE6Q36198340-37CE375E-B0EC-4038-A4E3-4C5FF36AF0DBQ36365583-590C2B96-0BB6-4138-9C58-C906F1F34382Q36407314-55FF3DD4-6FBD-4FC5-8B64-79AD873F40DFQ36419576-782AFDCA-CB29-415B-9E92-F3BAE4C04ABEQ37550515-BECD4049-65DB-42CE-9C51-315CD4279CE2Q37733512-DC33092A-D215-4ED6-AE28-FBE31E8002B8Q38093096-9444851B-81EA-4016-B270-9A9FAEE8694AQ38645740-9B07A931-A9D9-459A-80A8-C06DAD647581Q41834761-2A8ADC88-CEA2-473F-8C7E-3CAF3CB88C1AQ44230238-7E6C4E8C-3F3F-4C74-9428-301A709C1A90Q46864240-07F4419F-7203-4F59-8631-357C7B43BB8C
P2860
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@en
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@nl
type
label
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@en
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@nl
prefLabel
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@en
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@nl
P2093
P1476
Mycophenolate (CellCept) treat ...... y and inclusion body myositis.
@en
P2093
P304
P356
10.1016/S0022-510X(01)00478-6
P577
2001-04-01T00:00:00Z